CPA
VRTX icon

Capital Performance Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Performance Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$651K Buy
1,457
+807
+124% +$376K 0.04% 179
2025
Q4 		$295K Buy
650
+21
+3% +$9.05K 0.02% 319
2025
Q3 		$246K Buy
629
+28
+5% +$11.7K 0.04% 268
2025
Q2 		$267K Buy
601
+59
+11% +$27.2K 0.05% 178
2025
Q1 		$263K Buy
+542
New +$253K 0.06% 181
2024
Q4 		– Sell
-83
Closed -$38.5K – 2634
2024
Q3 		$38.5K Buy
+83
New +$39.9K 0.01% 420

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Performance Advisors's VRTX Position: Q1 2026 in Review

Capital Performance Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 124% in Q1 2026, buying an estimated $376K and bringing the position to 1,457 shares worth $651K. The position accounts for 0.04% of the portfolio, ranked #179.

Capital Performance Advisors first reported a position in VRTX in Q3 2024 and has held it in 6 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Capital Performance Advisors held 1,457 shares of Vertex Pharmaceuticals worth $651K as of Q1 2026.
  • Capital Performance Advisors bought 807 Vertex Pharmaceuticals shares in Q1 2026, an estimated $376K.
  • Vertex Pharmaceuticals made up 0.04% of Capital Performance Advisors's portfolio in Q1 2026, its #179 holding.
  • Capital Performance Advisors first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Capital Performance Advisors's 13F filing for Q1 2026, filed 7 May 2026.